The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage ...

Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business ...

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares are surging Thursday after the company announced plans to broaden its drug ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

With a market capitalization of just $1.9 billion, Recursion still provides a potentially good entry point for investors, but that's only if there are good reasons to think that its strategy will pan ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

Our extensive analysis of the health care sector leads us to GSK as a strong health care stock to consider. GSK a renowned global pharmaceutical company, offers an impressive portfolio.

Mankind's strong execution capabilities and robust brand equity align well with Bharat Serums and Vaccines' super-specialty ...

Before the trading day starts we bring you a digest of the key news and events that are likely to move markets. Today we look ...

Indian shares are set to open higher on Tuesday, tracking a rebound in global stocks ahead of the key U.S. inflation data and ...